High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Glenmark Pharmaceuticals Ltd (BOM:532296) reports robust Q4 growth, achieves debt-free status, and sets ambitious targets for FY27.
Partnership strategy has produced great pharma bargains—and left the company exposed.
Johnson & Johnson seems to have perfected the art of the biotech deal. Rather than spending billions on acquisitions, it has built much of its pharma empire through partnerships that capture huge upside for bargain prices. A biotech partnership is a bit like an open relationship: Your partner can always fall in love with someone else.
The U.S. Food and Drug Administration (FDA) has approved pivekimab sunirine-pvzy (sold under the brand name Decnupaz), a highly targeted therapy for adults dealing with an ultra-rare and aggressive form of blood cancer.
Holding a high-yield dividend portfolio in a taxable account at the 24% federal bracket means writing the IRS a $14,400 check every year on $60,000 of income that should have been yours. It repeats annually, forever, on the same dollars you already earned. This series exists because most readers know what a Roth IRA is ... The Dividend Stocks That Generate $60,000 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)
IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.
Q1 earnings show this Dividend King still looks built for the long term.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.